

30 August 2021

EFPIA Japan

**Propositions to Improve Scientific Validity and Transparency:  
EFPIA Japan Publishes Latest Position Papers on  
Cost-Effectiveness Assessment for Medicines**

TOKYO – 30 August 2021 – EFPIA Japan today published its latest position papers on the cost-effectiveness assessment system for medicines in Japan. The association's up-to-date policy recommendations are now available at [efpia.jp](http://efpia.jp). In 2015, before the introduction of the cost-effectiveness assessment system (CEA), EFPIA Japan put forth its policy recommendations "EFPIA Viewpoint: Health Technology Assessment Application in Select Markets and Implications for Japan". Since then, upon the introduction and development of the CEA system, EFPIA Japan has been clarifying its views and continuously calling for improvements to the system. In the latest publication, EFPIA Japan identifies operational issues of the system and challenges in the scientific validity of the assessments. To address the challenges that have become apparent in the course of the CEA processes after the full implementation of the system in 2019, EFPIA Japan is also in this paper proposing solutions to address those issues.

**1. EFPIA Japan's Basic Position on Cost-Effectiveness Assessment in Japan "For Improving Scientific Validity and Transparency"**

From a policy viewpoint, the paper identifies operational issues in the system and proposes solutions for better assessment of diverse values of medicines.

**2. EFPIA Japan's Basic Position on Cost-Effectiveness Assessment in Japan "Issues in Scientific Validity"**

From a scientific viewpoint, the paper identifies technical issues in cost-effectiveness analysis and assessment and proposes solutions for better assessment of diverse values of medicines.

EFPIA Japan as a policy partner continues to have dialogues with multiple stakeholders to establish a drug pricing system where diverse values of medicines are properly reflected.

**About EFPIA Japan** (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceutical companies operating in Japan. In 2020, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

**About EFPIA (European Federation of Pharmaceutical Industries and Associations)**

(<http://www.efpia.eu>)

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

**Contact:**

Yuko Kidoguchi

EFPIA Japan Messaging & Communications Committee

1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268

Bayer Holding Ltd.

Tel: 03-6266-7757

Email: [yuko.kidoguchi@bayer.com](mailto:yuko.kidoguchi@bayer.com)